Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 485

1.

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.

Gastroenterology. 2003 Feb;124(2):288-92.

PMID:
12557133
2.

Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.

Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A.

Gastroenterology. 2002 Oct;123(4):1006-12.

PMID:
12360461
3.

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

Arch Intern Med. 2000 Oct 23;160(19):2998-3003.

PMID:
11041909
4.

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group..

Ann Intern Med. 2003 Oct 7;139(7):539-46.

PMID:
14530224
5.

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.

Circulation. 2001 Nov 6;104(19):2280-8.

6.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group..

N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528.

7.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Weir MR, Sperling RS, Reicin A, Gertz BJ.

Am Heart J. 2003 Oct;146(4):591-604. Review.

PMID:
14564311
8.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069
9.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
10.

Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.

Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D.

J Rheumatol. 2002 Mar;29(3):467-73.

PMID:
11908558
11.
12.

An evidence-based evaluation of the gastrointestinal safety of coxibs.

Bombardier C.

Am J Cardiol. 2002 Mar 21;89(6A):3D-9D. Review.

PMID:
11909555
13.

The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.

Laine L.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):25-32. Review.

PMID:
12528071
14.

The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.

Florentinus SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HG.

Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):437-41. Erratum in: Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):669.

PMID:
15937867
16.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
17.

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Laine L, Maller ES, Yu C, Quan H, Simon T.

Gastroenterology. 2004 Aug;127(2):395-402.

PMID:
15300570
19.

Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.

Scheiman JM.

Cleve Clin J Med. 2002;69 Suppl 1:SI40-6. Review.

PMID:
12086292
20.

Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.

Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.

J Rheumatol. 2000 Aug;27(8):1876-83.

PMID:
10955327

Supplemental Content

Support Center